Abeid Athman (Omar).
@bin_abeid
Followers
2K
Following
10K
Media
545
Statuses
6K
Head of Oncology Department @KUTRRH. Fellow at European School of Oncology @ESOncology and @IEO. ASCO24 IDEA Awardee. Top 40under40 2024. Proud Kilifornian
Joined June 2011
RT @MarioBalsaMD: š§µ Non-metastatic gastroesophageal adenocarcinoma ā shifting landscape at #ESMOGI25. āŖļøFLOT > CROSS for OS.āŖļøā distant relā¦.
0
39
0
RT @Timothee_MD: The CONTACT-02 trial is now published! We already performed (and published in EJC) a sensitivity analysis based on digitizā¦.
0
7
0
RT @Elkhanany: Fantastic power summary by Dr @mfrimawi on HER2+ Breast Cancer and lessons learnt from recent trials. #bcsm @bcmhouston @BCā¦.
0
10
0
RT @roxboxfix: PARSIFAL-LONG.1st Line Rx of Palbo with ( Fulvestrant or Letrozole) in ER+Her2- MBC.Updated OS of PARSIFAL Ph II.419 of 486ā¦.
0
7
0
RT @StephenVLiu: Phase 2 ACHIEVE trial of high-dose aumolertinib for #EGFR NSCLC with brain metastases @JAMAOnc (n=63). RR 88.9%, intracranā¦.
0
13
0
RT @MaryCushmanMD: Do you dose reduce DOAC for extended prevention of VTE?.š Post hoc analysis of RENOVE trial of secondary prevention of Vā¦.
0
28
0
RT @drsarahsam: A nice patient friendly article on how metastases occur in breast cancer and how cells adapt to their metastatic environmenā¦.
0
47
0
RT @Dr_ElvinaA: Science progresses, but if patients canāt access it, we fail. We must bridge the gap between innovation and reality. #ASCO2ā¦.
0
30
0
RT @JAMouabbi: The study reflects real-world data from Italy š®š¹ āwhere access to care is streamlined. But in the U.S. šŗšø, without universaā¦.
0
4
0
RT @drsarahsam: Recent rationale in metastatic breast cancer for bringing ADCs into the 1st line has quoted very high 1st line attrition raā¦.
0
17
0
RT @abdullahayofel: Sleeping in Muzdalifa, no palaces no luxury buildings no family no expensive blankets.š®š¤š. A night where the rich and tā¦.
0
4K
0
RT @DrSGraff: A practice changing trial that IMMEDIATELY needs to be challenged. 2L TDXd only 10%, adj SOC was less than usual, and given Pā¦.
0
46
0
RT @jennifermarksmd: Certainly agree with @JordiRemon that DELLI was a very brave study; it appears though that ultra-low dose of IO stillā¦.
0
17
0
RT @AyaAbde15816258: Excited to share that I presented my poster today at #ASCO25! Thank you to everyone who shared their thoughts on thisā¦.
0
1
0
0
43
0
RT @stolaney1: Beautiful discussion by @KalinskyKevin . -Low TIL &N+ assoc w/ worse outcome in pts with pCR. - High ROR identified in aboutā¦.
0
11
0
RT @stolaney1: Brilliant discussion by @JavierCortesMD on APHINITY.If adjuvant treatments decrease distant events, is OS benefit really neeā¦.
0
47
0
RT @cancerphysicist: Iām SO delighted to finally see the STAR-TREC data reported š¤© #ESTRO25. Short course RT vs chemorad for organ preservaā¦.
0
59
0
RT @PBlanchardMD: SBRT (6*6Gy) is a new treatment option for small oral cavity cancers (T1-2) at risk of local recurrence after resection (ā¦.
0
56
0